Table 2. Use of concomitant treatments at baseline in patients with RAS blockade.
| Nifedipine (n=857) | Placebo (n=875) | |
|---|---|---|
| Antianginal drug | ||
| β blocker | 71.7 (%) | 72.9 (%) |
| Organic nitrate, as needed | 48.0 (%) | 48.9 (%) |
| Organic nitrate, daily maintenance | 41.0 (%) | 39.8 (%) |
| Other vasodilator | 5.7 (%) | 5.7 (%) |
| Any of the above | 97.8 (%) | 97.9 (%) |
| Any two of the above | 44.2 (%) | 45.6 (%) |
| Any three or four of the above | 11.8 (%) | 11.6 (%) |
| Lipid lowering | ||
| Statin | 62.0 (%) | 63.1 (%) |
| Fibrate | 7.9 (%) | 7.5 (%) |
| Other | 0.9 (%) | 1.4 (%) |
| Any of the above | 68.8 (%) | 69.2 (%) |
| Blood pressure lowering | ||
| ACE inhibitor | 89.7 (%) | 89.9 (%) |
| Angiotensin-II antagonist | 10.3 (%) | 10.1 (%) |
| Diuretic | 20.3 (%) | 23.3 (%) |
| Other | 3.6 (%) | 2.5 (%) |
| Any of the above | 100 (%) | 100 (%) |
| Other cardiovascular | ||
| Acetylsalicylic acid | 85.4 (%) | 84.8 (%) |
| Vitamin K antagonist | 4.8 (%) | 5.1 (%) |
| Cardiac glycoside | 1.1 (%) | 1.8 (%) |
| Amiodarone, sotalol or other antiarrhythmic | 4.1 (%) | 5.1 (%) |
Abbreviation: RAS, renin angiotensin system.